MeiraGTx Holdings Plc

Perceptive Advisors’ latest 555k‑share purchase of MeiraGTx (10.8m total, 1.16% stake) signals confidence in its gene‑therapy platform; watch regulatory milestones and warrant upside for future growth.

MeiraGTx insider sales reveal a 16% stake drop, hinting at possible confidence shifts amid volatile stock prices.

MeiraGTx insider moves show routine vesting, not panic—execs buying while covering taxes, hinting steady confidence in its gene‑therapy pipeline.